METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS

• US 20120230970A1
• Filed: 05/25/2012
• Published: 09/13/2012
• Est. Priority Date: 12/17/1999
• Status: Active Grant

• Current Assignee: Curemark LLC
• Original Assignee: Curemark LLC
• Inventors: FALLON, JOAN M.
• Granted Patent: US 8,613,918 B2
• Time in Patent Office: Days
• US Class Current: 424/94.2
• CPC Class Codes: A61B 5/1118 Determining activity level
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/165 Evaluating the state of mind, e.g. depression, anxiety
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61K 38/2235 Secretins
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 38/48 acting on peptide bonds (3.4)
• CPC Class Codes: A61K 38/4826 Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Y 302/0102 Alpha-glucosidase (3.2.1.20)
• CPC Class Codes: C12Y 304/21001 Chymotrypsin (3.4.21.1)
• CPC Class Codes: C12Y 304/21004 Trypsin (3.4.21.4)
• CPC Class Codes: G01N 2333/976 Trypsin; Chymotrypsin
• CPC Class Codes: Y10S 435/803 Physical recovery methods, e.g. chromatography, grinding
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.

Claims

1-86. -86. (canceled)

87. A method of selecting an individual with a pervasive development disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:

a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry; and

b. selecting the individual for treatment with a pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal.

89. The method of claim 87 or 88, wherein the individual is a child.

90. The method of claim 87 or 88, wherein the PDD is selected from Autism, Aspergers, ADD, or ADHD.

91. The method of claim 87 or 88, wherein the digestive enzymes comprise amylase, protease or lipase.

92. The method of claim 87 or 88 wherein photospectrometry comprises an enzymatic photospectrometry method.

93. The method of claim 92, wherein the level of chymotrypsin present in the fecal sample is determined at 30°

C.

94. The method of claim 87 or 88, wherein the individual has a symptom of PDD comprising an impairment in making eye contact with another individual, a lack of social interaction, a delay or lack of spoken language, a repetitive pattern of behavior, hyperactivity, a lack of attention, a lack of a formed bowel movement, a lack of toilet training, or any combination thereof.

95. The method of claim 87 or 88, wherein the measured fecal chymotrypsin level is sub-normal if it lies below 8.4 U/gram.

96. The method of claim 87 or 88, wherein the digestive enzymes comprise chymotrypsin, trypsin, cellulose, sucrose, or maltase.

88. A method of selecting an individual with a pervasive development disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:

a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry;

b. selecting the individual for treatment with the pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal; and

c. administering the pharmaceutical composition comprising one or more digestive enzymes if the individual is selected for treatment.

97. The method of claim 88, wherein administering the digestive enzymes reduces the frequency or severity of a symptom of PDD in the individual.